Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL)
Status:
Completed
Trial end date:
2014-02-20
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, open-label, Phase IV study to assess the efficacy,
tolerability, and safety of 2 initial dose levels of bexarotene capsules in participants with
refractory CTCL.
Phase:
Phase 4
Details
Lead Sponsor:
Bausch Health Americas, Inc. Valeant Pharmaceuticals International, Inc.